This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

BioMarin Announces Phase 1 Results For BMN-111 For Achondroplasia

Stock quotes in this article: BMRN

NOVATO, Calif., Sept. 26, 2012 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the completion of a Phase 1 study for BMN-111, an analog of C-type Natriuretic Peptide (CNP), for achondroplasia. The company expects to initiate a Phase 2 trial in mid-2013.

The Phase 1 study was a two-part, double-blind, placebo-controlled study in healthy adult males. Part 1 examined a series of single subcutaneous doses and Part 2 included ten days of either fixed dosing or dose escalation. The primary objective of the study was to evaluate safety, tolerability and pharmacokinetics (PK) of single and multiple doses of BMN-111 in 48 healthy adult volunteers.

BMN-111 was generally well-tolerated. Mild, transient, self-limited hypotension was observed. The majority of these cases were asymptomatic, and only observed upon assumption of an upright posture following recumbence. No dose-limiting toxicities were identified outside of these cardiovascular findings. Systemic exposure to BMN-111 was similar at these doses to what has been observed to cause growth in healthy and disease model animals. All adverse events were of mild severity. 

"We have identified a safe starting dose for treatment of achondroplastic children," stated Hank Fuchs, M.D., Chief Medical Officer of BioMarin. "Further, we have identified the likely side effects of excessive exposure, at least in the short-term, and we do expect BMN-111 to be well-tolerated in children. We are presently evaluating options for further development in various forms of achondroplasia."

Based on the results of the Phase 1 study, the design of a Phase 2 proof-of-concept and dose finding study is underway.  The goal of the program is to assess growth velocity as well as medical complications of achondroplasia, including non-growth endpoints. To better understand the nature of the disease, a study to collect consistent baseline growth measurements in children with achondroplasia was initiated in the second quarter of 2012. Participants in this study will be considered for enrollment in the Phase 2 study. 

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs